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Abstract Many applications of MRI are limited by an
inherently low sensitivity. Previous attempts to overcome
this insensitivity have focused on the use of MRI systems
with stronger magnetic fields. However, the gains that can
be achieved in this way are relatively small and increasing
the magnetic field invariably leads to greater technical
challenges. More recently, the development of a range of
techniques, which can be gathered under the umbrella term
of “hyperpolarization,” has offered potential solutions to the
low sensitivity. Hyperpolarization techniques have been
demonstrated to temporarily increase the signal available in
an MRI experiment by as much as 100,000-fold. This
article outlines the main hyperpolarization techniques that
have been proposed and explains how they can increase
MRI signals. With particular emphasis on the emerging
technique of dynamic nuclear polarization, the existing
preclinical cardiovascular applications are reviewed and the
potential for clinical translation is discussed.
Keywords Hyperpolarization . Dynamic nuclear
polarization . Parahydrogen-induced polarization . Optical
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Introduction
In recent years the development of cardiac magnetic
resonance imaging (CMR) has provided a valuable new
approach for the assessment of cardiac structure and
function. However, despite the enormous developments in
terms of hardware, software, and processing power that
have taken place, MRI remains an inherently sensitivity
limited technique and certain applications are restricted by
the low signal levels, e.g. multi-nuclear spectroscopy for
the assessment of metabolism [1]. The low sensitivity is
due to the fact that the interactions between the static
magnetic field of the MRI system and the molecules of the
body are small. The standard approach to overcome this
sensitivity limitation has been to increase the magnetic field
strength of the MRI system, such that MRI systems with
static field strengths of 3 T are now becoming common-
place for clinical practice and ultra-high field strength
systems at 7 T or above are being used in the research
setting. However, the gains in signal that can be achieved
by increasing field strength are limited because the signal-
to-noise ratio (SNR) scales approximately linearly with the
magnetic field strength. Added to this limited increase in
sensitivity are the increasing technical and safety challenges
that are faced at higher field strengths in terms of B1 field
homogeneity, specific absorption rate (SAR) levels, system
costs, etc.
An alternative approach to the issue of low sensitivity is
offered by a range of techniques that are commonly
described under the envelope of “hyperpolarization” [2–
5]. These techniques work by temporarily increasing the
strength of the MR signal, in some cases by as much as
100,000-fold [2, 6]. All hyperpolarization techniques
require the injection, infusion, or inhalation of a substance
that has been previously prepared in a separate system and
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the large increases in sensitivity have been utilized in a
wide range of different applications, including lung
imaging [4], tumor staging [7, 8], and the assessment of
cardiovascular diseases [9••, 10•, 11••]. All hyperpolarized
techniques also suffer from the same inherent problem;
the increased sensitivity is transient, and so the decay of the
increased signal must be carefully controlled within the
experiment [1].
The aim of this review is to describe the main types of
hyperpolarization techniques that are available and, with
particular focus on the emerging technique of dynamic
nuclear polarization (DNP), to describe the existing
literature on the preclinical application of hyperpolarized
agents to study the heart. The review will then close with a
discussion of the potential for translation of the DNP
technique into humans and the main challenges that need to
be overcome.
Hyperpolarization Techniques
The basis of magnetic resonance imaging lies in the
interaction between the static magnetic field of the MRI
system and the molecules of the body. When placed in the
magnetic field, the molecules act like small bar magnets,
aligning themselves in one of two orientations, either in the
same direction as the field or opposed to it. The signal
generated by the MRI system is then proportional to the
difference in the number of molecules aligned in the two
orientations, referred to as the polarization. At normal
clinical magnetic field strengths and room temperature, the
polarization is very small (e.g. at 3 T, the difference
between the number of molecules in the different orienta-
tions is only 10 molecules in every million). The aim of
hyperpolarization techniques is to artificially increase the
polarization, and thus the signal from the MRI system, by
forcing more of the molecules into one orientation.
Currently, there are four main approaches used to generate
hyperpolarized compounds, which can subsequently act as
high-sensitivity tracers in an MRI experiment. These are
brute force polarization [5], optical pumping of noble gases
[4], parahydrogen-induced polarization (PHIP) [2], and
dynamic nuclear polarization (DNP) [3, 6].
Brute Force Polarization
The brute force approach is perhaps the simplest to
understand but currently the least effective. It involves
placing the sample to be polarized in a very high magnetic
field at extremely low temperatures. In these conditions the
sample will naturally approach a high level of polarization
because the polarization achieved by a sample increases with
the magnitude of the static magnetic field and decreases with
the temperature. However the brute force approach is limited
because the size of the polarization levels that can be
achieved are relatively small and the sample can take a long
time to approach the high polarization level. There are also
practical difficulties in returning the sample to the liquid
state for use in an in vivo experiment [5].
Optical Pumping
Optical pumping of the noble gases, particularly helium (3He)
and xenon (129Xe), has generated a great deal of interest in
recent years due to its direct applicability to the imaging of
the lungs [4]. The sample to be polarized is mixed with
either an alkali-metal vapor or a vapor of metastable atoms.
The mixture is then irradiated with circularly polarized light
from a laser source, which is absorbed by the alkali or
metastable atoms, increasing the polarization of their
electrons [5]. This high level of polarization is then passed
on to the nuclei of the noble gas through collisions. MR
images of the lungs generated following the inhalation of
these hyperpolarized noble gases can then be used to detect
changes in ventilation, perfusion, and lung microstructure
associated with diseases such as chronic obstructive pulmo-
nary disease (COPD) and asthma [4].
Parahydrogen-Induced Polarization
PHIP, also referred to as PASADENA, utilizes a highly
polarized form of molecular hydrogen, known as para-
hydrogen, to increase the polarization of a specific nucleus,
typically carbon (13C) or nitrogen (15N), within a chosen
molecule [2]. The first step in the PHIP technique is to
generate high levels of parahydrogen. Molecular hydrogen
is normally found in two different forms, orthohydrogen
and parahydrogen, in a 3:1 ratio. At low temperatures, and
in the presence of a suitable catalyst, the relative abundance
of parahydrogen can be increased to nearly 100%. The
parahydrogen produced is then involved in a hydrogenation
reaction, in the presence of a second catalyst, that produces
the molecule to be hyperpolarized. Finally, the high
polarization of the parahydrogen is transferred to the 13C
or 15N nuclei by either cycling the magnetic field or
applying a sequence of RF pulses [5]. The PHIP technique
can rapidly generate extremely high levels of polarization
(> 40%) using relatively simple and inexpensive apparatus
[2]. However, the technique is limited by the specificity of
the chemical reaction required and the need to remove the
hydrogenation reaction catalyst before injection.
Dynamic Nuclear Polarization
The final technique, and the focus of the rest of this article,
is dynamic nuclear polarization (DNP) [3, 6]. As with
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PHIP, the DNP technique is used to enhance the polariza-
tion of a specific nucleus (again typically 13C or 15N)
within a particular molecule. It requires the mixing of the
molecule to be hyperpolarized with a source of free
electrons, known as a radical. The mixed sample is then
placed in a high magnetic field (typically 3.35 T) and
rapidly frozen in liquid helium, reducing the sample
temperature to approximately 1 K. In these conditions,
the free electrons are nearly 100% polarized (ie, all
aligned in the same direction as the static magnetic
field), whereas the nuclear spins of the sample are still
relatively poorly polarized. The high electron polariza-
tion can then be transferred to the nuclear spins through
the irradiation of the sample with microwave energy at
a specific frequency, which is related to the magnetic
field strength and the atomic properties of the nuclei
and radical within the sample. Further details of the
processes involved in this polarization transfer are more
thoroughly described in the review by Comment et al.
[3].
Despite the high level of polarization that can be
achieved, the biological application of DNP has been
limited by the need for the hyperpolarization process to
take place in the solid state. This limitation was removed by
the development of the dissolution DNP process [6],
whereby the highly polarized solid sample is rapidly
brought into the liquid state, retaining a large proportion
of the enhanced polarization. The process, first described
by Ardenkjaer-Larsen and colleagues in 2003, requires
the rapid melting of the hyperpolarized sample with a
bolus of superheated liquid and generates an injectable
sample that can be used as an in vivo MR contrast
agent [6].
Cardiovascular Applications
Hyperpolarization techniques have been explored in a range
of cardiovascular applications. In most examples, the
techniques of PHIP or DNP have been used to generate
hyperpolarized 13C-labeled molecules that have subse-
quently been used for angiography, perfusion assessment,
catheter tracking, or metabolic imaging [12•]. For the
vascular imaging applications (angiography, perfusion,
catheter tracking) the molecules used have either been
non-endogenous (e.g. hydroxyethylpropionate generated by
PHIP and 1,1-bis(hydroxymethyl)-cyclopropane-(1-13C,
D8) generated using DNP) or endogenous molecules that
were metabolically inactive (e.g. 13C-urea generated by
DNP) [12•]. For metabolic imaging a range of different
metabolically active compounds have been explored (e.g.
pyruvate generated by DNP [12•] and succinate generated
by PHIP [13]).
Angiography
With hyperpolarized 13C-labeled tracer molecules, the large
SNR and the fact that there is virtually no background
signal generates an extremely high contrast-to-noise ratio
(CNR), which is well suited to angiographic applications
[14]. As such, the use of hyperpolarized agents for
angiography has been widely explored [15, 16], with
particular focus being given to imaging of the coronary
[17] and pulmonary [18] arteries. The long transverse
relaxation times of 13C molecules favor the use of single
shot imaging techniques (e.g. trueFISP, EPI) [1] and so high
temporal resolutions (< 300 ms) have been demonstrated.
The lack of background signal has also led to the use of
projection imaging techniques with reasonable in-plane
resolutions (~ 1 mm). However, the imaging of 13C-labeled
molecules places large demands on the imaging gradients
of the MRI system because the gyromagnetic ratio of 13C is
¼ that of 1H. This leads to the need for more powerful
gradient amplifiers and, when combined with rapid imaging
techniques, may place limits on the ultimate spatial
resolution that is achievable for angiographic applications.
Perfusion
CMR assessments of myocardial perfusion are usually
based on the first pass of a gadolinium-based contrast
agent through the heart. The contrast agent shortens the T1
of the myocardium and increases the signal intensity of well
perfused tissues on T1-weighted images. However, this
indirect assessment of perfusion can lead to difficulties in
the absolute quantification of myocardial perfusion [19]. In
contrast, hyperpolarized perfusion measurements rely
directly on the signal obtained from the hyperpolarized
tracer and so allow for easier absolute quantification. The
continual decay of the hyperpolarized signal obviously
needs to be taken into account and represents a limitation of
the technique, but novel acquisition schemes and quantita-
tive models can be developed to account for these effects
[20]. The application of hyperpolarized tracers for the
quantitative assessment of perfusion has been demonstrated
in the pig myocardium [1] and the rat brain [21].
Catheter Tracking
The inherent lack of background signal when using hyper-
polarized 13C tracers also offers potential for use in
interventional MR experiments. As a demonstration of this,
hyperpolarized tracers have been used to enable passive
catheter tracking through the aorta of a pig [22]. Through
the use of a specially modified three-lumen catheter, the
flowing hyperpolarized tracer was directly imaged using a
3D back-projection imaging technique that offered frame
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rates of 1.4 frames/s. The obvious limitation for hyper-
polarized tracers in this application is the need to continually
refresh the tracer, as the signal will decay through relaxation
mechanisms and the continuous RF pulsing. However, the
rapid polarization offered by the PHIP technique could
provide a solution to this problem.
Metabolic Spectroscopy and Imaging
There is a growing body of evidence to suggest that
alterations in metabolic substrate utilization may be a cause,
rather than a symptom, of cardiovascular disease [23–25].
To increase our understanding of alterations in substrate
selection, it is necessary to use an in vivo method that can
repeatedly measure metabolism noninvasively. This would
allow the metabolic changes which occur during disease
progression to be assessed and would open a new window
on the development of possible metabolic treatments.
Magnetic resonance spectroscopy (MRS) using carbon
(13C) is ideally suited to the study of metabolism due to
the extensive range of compounds that can be detected and
the ability to attribute signals to the different carbon atoms
within individual molecules. 13C studies of cardiac metab-
olism have been conducted since the early 1980s when the
first experiments were performed on the isolated perfused
rat heart by Bailey et al. [26] using 13C-enriched sodium
acetate. A wealth of work has since followed allowing
detailed studies of metabolic substrate selection in normal
[27], ischemic [28], and diabetic [29] hearts. However, the
clinical utility of 13C MRS experiments has been limited
due to a combination of the inherently low sensitivity of
MRS, the low in vivo concentrations, and the low natural
abundance of 13C. As such, the majority of cardiac studies
have been performed on ex vivo hearts, perfused with 13C-
enriched molecules and using very long scan times. This
has resulted in the ability to only study metabolic steady
state conditions [30] and, so far, there have only been a
limited number of in vivo studies [31] or studies of non–
steady state rates of oxidative metabolism [32] using non-
hyperpolarized techniques.
The advent of hyperpolarization, particularly with DNP,
has provided the ability to generate metabolically active
“tracers” that can be injected into an in vivo experiment.
The high SNR provided allows both the visualization of the
injected molecule and also the downstream metabolic
products to which the 13C label is transferred. To date, the
majority of experiments with this method have focused on
the key metabolic molecule pyruvate, labeled with 13C at
the first carbon position ([1-13C]pyruvate). Pyruvate is
metabolically important because it sits at the junction of
metabolism between glycolysis and the tricarboxylic acid
(TCA) cycle (Fig. 1) and therefore allows a range of
different metabolic pathways to be explored. [1-13C]
pyruvate also offers practical advantages as it is easily
hyperpolarized, is rapidly taken up into cells and metabo-
lized, and has a long relaxation time (T1 of ~60 s) meaning
that the hyperpolarized signal persists for a long time.
In the first application of DNP-generated hyperpolar-
ized [1-13C]pyruvate in the perfused rat heart, Merritt et
al. [10] showed the conversion of infused pyruvate into
lactate, alanine, bicarbonate, and carbon dioxide. The
lactate observed has since been shown to be due to rapid
exchange of the 13C label with endogenous lactate via the
enzyme lactate dehydrogenase (LDH) [33]. Similarly, the
alanine signal is generated by the transamination reaction
mediated by alanine aminotransferase (AAT). The bicar-
bonate resonance is observed due to the transformation of
pyruvate into acetyl-CoA via the enzyme pyruvate dehy-
drogenase (PDH). During this enzymatic transfer, the 13C
label is cleaved from the pyruvate molecule as 13CO2,
which is in a rapid, pH-dependant equilibrium with
bicarbonate under the action of the enzyme carbonic
anhydrase (CA). Therefore, the observation of bicarbon-
ate can be seen as a surrogate marker of flux through
PDH. The ability to measure flux through PDH could be
vitally important as PDH is one of the key regulatory
enzymes of the glucose–fatty acid (or Randle) cycle, and
is therefore a key determinant of substrate selection in
the heart [34].
In the first use of hyperpolarized [1-13C]pyruvate in the
in vivo rodent heart, Schroeder et al. demonstrated that not
only could the metabolic fate of [1-13C]pyruvate be
monitored in vivo, but that physiological (overnight fasting)
and pathological (type 1 diabetes) modulation of PDH flux
could be observed [11••, 35]. They further demonstrated
that the in vivo assessment of PDH flux in their model of
type 1 diabetes correlated significantly with the severity of
the disease. This work was extended by Atherton et al. [36],
who demonstrated that the in vivo assessment of PDH flux
obtained using hyperpolarized MRS correlated significantly
with the ex vivo activity of the PDH enzyme as assessed by
a traditional enzymatic activity assay. In this work a period
of high fat feeding was used to reduce PDH activity, and
dichloroacetate (a pyruvate analogue known to increase
PDH activity) was infused to generate a range of in vivo
PDH activities.
Further work has since shown the applicability of the
DNP technique to the study of myocardial ischemia in the
perfused heart [37, 38••], where elevated levels of lactate
were observed following a period of global ischemia. Also,
the ability of hyperpolarized MRI to assess intracellular pH
in the in vivo heart has been demonstrated [39•]. As
mentioned previously, the 13CO2 produced when [1-
13C]
pyruvate is decarboxylated by PDH is in a rapid, pH-
dependant equilibrium with bicarbonate (H13CO3-). By
measuring the relative intensities of the 13CO2 and
Curr Cardiovasc Imaging Rep (2011) 4:108–115 111
H13CO3- resonances, it is possible to calculate the intracel-
lular pH using the Henderson-Hasselbalch equation [39•].
Other metabolic pathways have been monitored in the
heart. The use of [2-13C]pyruvate has been shown to provide
a method for the real-time assessment of metabolism through
the TCA cycle (Fig. 1) [38••]. The use of pyruvate that is
labeled with 13C at the second carbon position means that the
13C molecule is no longer cleaved into 13CO2 but is carried
into acetyl-CoA instead, allowing assessment of flux into the
TCA cycle. In this work, Schroeder et al. demonstrated the
ability to visualize the conversion of [2-13C]pyruvate into the
downstream metabolites citrate, glutamate, and acetylcarni-
tine, and further, that the flux into the TCA cycle was
reduced following a period of global ischemia.
One of the key issues to consider with the application of
metabolic imaging using the DNP technique is that the
molecules being injected are, by their very nature, metabol-
ically active. They are also generally injected at supra-
physiological concentrations. For example, in vivo
experiments with [1-13C]pyruvate have frequently been
carried out with injections of ~80 mM pyruvate, when the
normal physiological concentration is ~60 μM [36]. As such,
hyperpolarized compounds generated by DNP cannot be
considered as “tracers” in the strictest sense of the word and
the physiological consequences of the injected compound
need to be considered [36, 40, 41]. To this aim, recent work
has demonstrated that, due to saturation of either the
mitochondrial pyruvate transporter or PDH itself, lower
concentrations of pyruvate can be injected without affecting
the level of bicarbonate signal observed [41, 42••]. Atherton
et al. [36] have also shown that following a 1 mL injection of
80 mM pyruvate into the rat, the maximum plasma
concentration reached is only 250 μM. This relatively low
concentration of pyruvate in the plasma, due most likely to
the small volume injected and the rapid systemic uptake of
pyruvate, is in line with pyruvate levels seen during exercise.
All of the work discussed so far on metabolic assessment
with DNP has involved the use of unlocalized or “global”
MR spectroscopy techniques. However, to visualize meta-
bolic heterogeneity in the diseased heart, imaging techni-
ques are required to distinguish healthy myocardium from
diseased myocardium. As an initial approach to this,
Golman et al. [9••] demonstrated the use of a single slice,
chemical shift imaging (CSI) acquisition scheme to allow
the spatial localization of pyruvate, lactate, alanine, and
bicarbonate following an injection of [1-13C]pyruvate into
the pig heart. They further demonstrated localized alter-
ations in the bicarbonate image following a period of
ischemia caused by temporary occlusion of the left
circumflex artery. The spatial resolution in this study was
7.5×7.5×20 mm and the total acquisition time was 13.4 s
(non–ECG gated acquisition). This resolution has since
been surpassed by Lau et al. [42••], who demonstrated a
cardiac and respiratory gated, single-shot spiral acquisition
technique with a spatial resolution of 3.7×3.7×10 mm and
the ability to image any specific metabolite in ~80 ms. With
this technique, whole heart coverage (6 slices) can be
achieved within 3 heartbeats.
Fig. 1 An illustration of the
metabolic pathways that have
been examined with hyperpolar-
ized MRI using the dynamic
nuclear polarization (DNP)
technique. AAT, alanine amino-
transferase; CA, carbonic anhy-
drase; CAT, carnitine
acetyltransferase; FM, fumarase;
GLM, glutaminase; LDH, lac-
tate dehydrogenase
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Conclusions
The significant increases in MR signal that can be achieved
with hyperpolarization techniques offer real promise in
overcoming the sensitivity limitations of certain MRI
applications. Dissolution DNP, and to a lesser extent PHIP,
appear set to provide clinically relevant information in the
cardiovascular applications of angiography, perfusion,
catheter tracking, and metabolic imaging. However, neither
DNP nor PHIP techniques have yet been transferred into
humans and, until this milestone is achieved, their true
clinical potential remains to be proven. In the case of DNP,
this achievement appears to be imminent, with the first
trials in man scheduled for late 2010 at the University of
San Francisco in the study of prostate cancer. The
conversion of DNP hyperpolarized [1-13C]pyruvate into
[1-13C]lactate has been demonstrated to be a sensitive
marker for tumor diagnosis and response to treatment [7, 8]
and, therefore, the application of DNP in the field of
oncology is generating a great deal of interest.
GE Healthcare has pioneered the development of a DNP
polarizer that is capable of producing clinical-quality
tracers, and the ability to polarize DNP tracers in sufficient
quantities for human application has also been demonstrat-
ed [43]. Further work is still required to optimize the DNP
technique for clinical applications, but significant steps
have been taken in terms of increasing the polarization
levels that can be achieved [44, 45], improving the MR
pulse sequences used [46, 47], and improving the detection
of hyperpolarized signals with new RF coils. The other
significant area of current research has been the develop-
ment of new tracer molecules to assess different metabolic
pathways (Fig. 1). Hyperpolarized bicarbonate has been
demonstrated for the measurement of extracellular pH [48],
hyperpolarized glutamine has been demonstrated as a
technique for assessing cellular proliferation [49], and
hyperpolarized fumarate has been demonstrated as a marker
of cellular necrosis [50].
The final translation of DNP into the clinical setting will
undoubtedly present regulatory challenges that will need to
be overcome. The delivery of any hyperpolarized tracer
will require the removal of the electron radical before
injection (a process which can be achieved by filtration of
the dissolved tracer) and the impact of injecting supra-
physiological concentrations of metabolically active com-
pounds (as discussed above) will need to be carefully
investigated. There will also be a need for rigorous and
rapid quality control of the dissolved compounds in terms
of the polarization level, pH, temperature, etc. before
injection into patients.
In summary, there is clear potential for hyperpolarized
techniques, particularly DNP, to have a significant impact
in the future of MRI. The cardiovascular applications that
have been proposed look promising but require further
development and greater validation against existing techni-
ques. The potential for DNP in the area of metabolic
imaging appears particularly strong. The ability to directly
image the conversion of an injected compound into its
downstream metabolites offers a distinct advantage over
positron emission tomography, with the additional benefit
of no ionizing radiation. There are still technical, practical,
and regulatory hurdles to overcome but the gains in signal
that can be achieved with hyperpolarization could provide
unique tools to assess the heart.
Acknowledgments For their constant hard work, enthusiasm, and
support, I would like to thank all of the members of the Cardiac
Metabolism Research Group (CMRG) in Oxford, particularly Prof.
Kieran Clarke, Prof. Sir George Radda, Dr. Marie Schroeder, Dr.
Helen Atherton, Dr. Lowri Cochlin, Mr. Daniel Ball, and Mr. Michael
Dodd. I would also like to acknowledge financial support from the
British Heart Foundation, the Medical Research Council, and the
Wellcome Trust and equipment support from GE Healthcare and
Oxford Instruments Molecular Biotools.
Disclosure No potential conflict of interest relevant to this article
was reported.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
Papers of particular interest, published recently have been
highlighted as:
• Of importance
•• Of major importance
1. Mansson, S., E. Johansson, P. Magnusson, et al., 13C imaging-a
new diagnostic platform. Eur Radiol, 2006. 16(1): p. 57–67.
2. Bhattacharya, P., B.D. Ross and R. Bunger, Cardiovascular
applications of hyperpolarized contrast media and metabolic
tracers. Exp Biol Med (Maywood), 2009. 234(12): p. 1395–416.
3. Comment, A., B. van den Brandt, K. Uffmann, et al., Design and
performance of a DNP prepolarizer coupled to a rodent MRI
scanner. Concepts in Magnetic Resonance Part B-Magnetic
Resonance Engineering, 2007. 31B(4): p. 255–269.
4. Fain, S.B., F.R. Korosec, J.H. Holmes, et al., Functional lung
imaging using hyperpolarized gas MRI. J Magn Reson Imaging,
2007. 25(5): p. 910–23.
5. Viale, A., F. Reineri, D. Santelia, et al., Hyperpolarized agents for
advanced MRI investigations. Q J Nucl Med Mol Imaging, 2009.
53(6): p. 604–17.
6. Ardenkjaer-Larsen, J.H., B. Fridlund, A. Gram, et al., Increase in
signal-to-noise ratio of > 10,000 times in liquid-state NMR. Proc
Natl Acad Sci U S A, 2003. 100(18): p. 10158–63.
7. Day, S.E., M.I. Kettunen, F.A. Gallagher, et al., Detecting tumor
response to treatment using hyperpolarized 13C magnetic resonance
imaging and spectroscopy. Nat Med, 2007. 13(11): p. 1382–7.
Curr Cardiovasc Imaging Rep (2011) 4:108–115 113
8. Golman, K., R.I. Zandt, M. Lerche, et al., Metabolic imaging by
hyperpolarized 13C magnetic resonance imaging for in vivo
tumor diagnosis. Cancer Res, 2006. 66(22): p. 10855–60.
9. •• Golman, K., J.S. Petersson, P. Magnusson, et al., Cardiac
metabolism measured noninvasively by hyperpolarized 13C MRI.
Magn Reson Med, 2008. 59(5): p. 1005–13. This article
demonstrates the potential for hyperpolarized MRI to image the
regional distribution of different metabolic products in normal
and post-ischemic hearts.
10. • Merritt, M.E., C. Harrison, C. Storey, et al., Hyperpolarized 13C
allows a direct measure of flux through a single enzyme-catalyzed
step by NMR. Proc Natl Acad Sci U S A, 2007. 104(50): p.
19773–7. This article demonstrates the utility of hyperpolarized
pyruvate in the perfused heart and shows that altered PDH flux
can be assessed with high temporal resolution.
11. •• Schroeder, M.A., L.E. Cochlin, L.C. Heather, et al., In vivo
assessment of pyruvate dehydrogenase flux in the heart using
hyperpolarized carbon-13 magnetic resonance. Proc Natl Acad
Sci U S A, 2008. 105(33): p. 12051–6. This is the first manuscript
to use hyperpolarized pyruvate to assess the in vivo rat heart and
to demonstrate the alterations to in vivo PDH flux caused by
overnight fasting and type 1 diabetes.
12. • Golman, K. and J.S. Petersson, Metabolic imaging and other
applications of hyperpolarized 13C1. Acad Radiol, 2006. 13(8):
p. 932–42. This is an excellent review of the preliminary work
exploring the potential applications of hyperpolarized MRI.
13. Ross, B.D., P. Bhattacharya, S. Wagner, et al., Hyperpolarized MR
imaging: neurologic applications of hyperpolarized metabolism.
AJNR Am J Neuroradiol, 2010. 31(1): p. 24–33.
14. Golman, K., J.H. Ardenkjaer-Larsen, J.S. Petersson, et al.,
Molecular imaging with endogenous substances. Proc Natl Acad
Sci U S A, 2003. 100(18): p. 10435–9.
15. Golman, K., O. Axelsson, H. Johannesson, et al., Parahydrogen-
induced polarization in imaging: subsecond (13)C angiography.
Magn Reson Med, 2001. 46(1): p. 1–5.
16. Svensson, J., S. Mansson, E. Johansson, et al., Hyperpolarized
13C MR angiography using trueFISP. Magn Reson Med, 2003.
50(2): p. 256–62.
17. Olsson, L.E., C.M. Chai, O. Axelsson, et al., MR coronary
angiography in pigs with intraarterial injections of a hyperpolarized
13C substance. Magn Reson Med, 2006. 55(4): p. 731–7.
18. Ishii, M., K. Emami, S. Kadlecek, et al., Hyperpolarized 13C MRI
of the pulmonary vasculature and parenchyma. Magn Reson Med,
2007. 57(3): p. 459–63.
19. Schwitter, J., Myocardial perfusion imaging by cardiac magnetic
resonance. J Nucl Cardiol, 2006. 13(6): p. 841–54.
20. Johansson, E., L.E. Olsson, S. Mansson, et al., Perfusion
assessment with bolus differentiation: a technique applicable to
hyperpolarized tracers. Magn ResonMed, 2004. 52(5): p. 1043–51.
21. Johansson, E., S. Mansson, R. Wirestam, et al., Cerebral
perfusion assessment by bolus tracking using hyperpolarized
13C. Magn Reson Med, 2004. 51(3): p. 464–72.
22. Magnusson, P., E. Johansson, S. Mansson, et al., Passive catheter
tracking during interventional MRI using hyperpolarized 13C.
Magn Reson Med, 2007. 57(6): p. 1140–7.
23. Horowitz, J.D. and J.A. Kennedy, Time to address the cardiac
metabolic “triple whammy” ischemic heart failure in diabetic
patients. J Am Coll Cardiol, 2006. 48(11): p. 2232–4.
24. Neubauer, S., The failing heart—an engine out of fuel. N Engl J
Med, 2007. 356(11): p. 1140–51.
25. Stanley, W.C., F.A. Recchia and G.D. Lopaschuk, Myocardial
substrate metabolism in the normal and failing heart. Physiol
Rev, 2005. 85(3): p. 1093–129.
26. Bailey, I.A., D.G. Gadian, P.M. Matthews, et al., Studies of
metabolism in the isolated, perfused rat heart using 13C NMR.
FEBS Lett, 1981. 123(2): p. 315–8.
27. Lloyd, S., C. Brocks and J.C. Chatham, Differential modulation of
glucose, lactate, and pyruvate oxidation by insulin and dichlor-
oacetate in the rat heart. Am J Physiol Heart Circ Physiol, 2003.
285(1): p. H163–72.
28. Sherry, A.D., C.R. Malloy, P. Zhao, et al., Alterations in substrate
utilization in the reperfused myocardium: a direct analysis by 13C
NMR. Biochemistry, 1992. 31(20): p. 4833–7.
29. Chatham, J.C. and A.M. Seymour, Cardiac carbohydrate metab-
olism in Zucker diabetic fatty rats. Cardiovasc Res, 2002. 55(1):
p. 104–12.
30. Malloy, C.R., A.D. Sherry and F.M. Jeffrey, Carbon flux through
citric acid cycle pathways in perfused heart by 13C NMR
spectroscopy. FEBS Lett, 1987. 212(1): p. 58–62.
31. Ziegler, A., C.E. Zaugg, P.T. Buser, et al., Non-invasive measure-
ments of myocardial carbon metabolism using in vivo 13C NMR
spectroscopy. NMR Biomed, 2002. 15(3): p. 222–34.
32. Malloy, C.R., J.R. Thompson, F.M. Jeffrey, et al., Contribution of
exogenous substrates to acetyl coenzyme A: measurement by 13C
NMR under non-steady-state conditions. Biochemistry, 1990. 29
(29): p. 6756–61.
33. Kettunen, M.I., D.E. Hu, T.H. Witney, et al., Magnetization
transfer measurements of exchange between hyperpolarized [1-
13C]pyruvate and [1-13C]lactate in a murine lymphoma. Magn
Reson Med, 2010. 63(4): p. 872–80.
34. Randle, P.J., Regulatory interactions between lipids and carbohy-
drates: the glucose fatty acid cycle after 35 years. Diabetes Metab
Rev, 1998. 14(4): p. 263–83.
35. Tyler, D.J., M.A. Schroeder, L.E. Cochlin, et al., Application of
hyperpolarized magnetic resonance in the study of cardiac
metabolism. Applied Magnetic Resonance, 2008. 34(3–4): p.
523–531.
36. Atherton, H.J., M.A. Schroeder, M.S. Dodd, et al., Validation of
the in vivo assessment of pyruvate dehydrogenase activity using
hyperpolarised (13)C MRS. NMR Biomed, 2010.
37. Merritt, M.E., C. Harrison, C. Storey, et al., Inhibition of
carbohydrate oxidation during the first minute of reperfusion
after brief ischemia: NMR detection of hyperpolarized 13CO2
and H13CO3. Magn Reson Med, 2008. 60(5): p. 1029–36.
38. •• Schroeder, M.A., H.J. Atherton, D.R. Ball, et al., Real-time
assessment of Krebs cycle metabolism using hyperpolarized 13C
magnetic resonance spectroscopy. FASEB J, 2009. 23(8): p.
2529–38. This article demonstrates the first application of [2-13C]
pyruvate for the assessment of real-time flux through the TCA
cycle and the alterations to this flux that are seen following global
ischemia in the perfused heart.
39. • Schroeder, M.A., P. Swietach, H.J. Atherton, et al., Measuring
intracellular pH in the heart using hyperpolarized carbon dioxide
and bicarbonate: a 13C and 31P magnetic resonance spectroscopy
study. Cardiovasc Res, 2010. 86(1): p. 82–91. This article details
the in vivo utilization of [1-13C]pyruvate for the assessment of
intracellular pH in the heart with high temporal resolution.
40. Moreno, K.X., S.M. Sabelhaus, M.E. Merritt, et al., Competition of
pyruvate with physiological substrates for oxidation by the heart:
implications for studies with hyperpolarized [1-13C]pyruvate. Am
J Physiol Heart Circ Physiol, 2010. 298(5): p. H1556–64.
41. Schroeder, M.A., H.J. Atherton, L.E. Cochlin, et al., The effect of
hyperpolarized tracer concentration on myocardial uptake and
metabolism. Magn Reson Med, 2009. 61(5): p. 1007–14.
42. •• Lau, A.Z., A.P. Chen, N.R. Ghugre, et al., Rapid multislice
imaging of hyperpolarized (13)C pyruvate and bicarbonate in the
heart. Magn Reson Med, 2010. A new acquisition scheme is
presented which allows for rapid, cardiac-gated acquisition of
metabolic images with high spatial and temporal resolution.
43. Comment, A., J. Rentsch, F. Kurdzesau, et al., Producing over
100 ml of highly concentrated hyperpolarized solution by means
of dissolution DNP. J Magn Reson, 2008. 194(1): p. 152–5.
114 Curr Cardiovasc Imaging Rep (2011) 4:108–115
44. Jannin, S., A. Comment, F. Kurdzesau, et al., A 140 GHz
prepolarizer for dissolution dynamic nuclear polarization. J Chem
Phys, 2008. 128(24): p. 241102.
45. Johannesson, H., S. Macholl and J.H. Ardenkjaer-Larsen, Dy-
namic Nuclear Polarization of [1-13C]pyruvic acid at 4.6 tesla. J
Magn Reson, 2009. 197(2): p. 167–75.
46. Cunningham, C.H., A.P. Chen, M.J. Albers, et al., Double spin-
echo sequence for rapid spectroscopic imaging of hyperpolarized
13C. J Magn Reson, 2007. 187(2): p. 357–62.
47. Cunningham, C.H., A.P. Chen, M. Lustig, et al., Pulse sequence
for dynamic volumetric imaging of hyperpolarized metabolic
products. J Magn Reson, 2008. 193(1): p. 139–46.
48. Gallagher, F.A., M.I. Kettunen, S.E. Day, et al., Magnetic
resonance imaging of pH in vivo using hyperpolarized 13C-
labelled bicarbonate. Nature, 2008. 453(7197): p. 940–3.
49. Gallagher, F.A., M.I. Kettunen, S.E. Day, et al., 13C MR
spectroscopy measurements of glutaminase activity in human
hepatocellular carcinoma cells using hyperpolarized 13C-
labeled glutamine. Magn Reson Med, 2008. 60(2): p. 253–
7.
50. Gallagher, F.A., M.I. Kettunen, D.E. Hu, et al., Production of
hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a
marker of cell necrosis and treatment response in tumors. Proc
Natl Acad Sci U S A, 2009. 106(47): p. 19801–6.
Curr Cardiovasc Imaging Rep (2011) 4:108–115 115
